Leiden Dworak serves as See Remarks at TScan Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Leiden Dworak has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 20, 2026 involved receiving (via award) 100,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 20, 2026 | TCRX | $0 | Award | 100,000 | $N/A | Discretionary |
Leiden Dworak currently holds 100,000 shares of TScan Therapeutics, Inc. (TCRX), valued at approximately $0. This represents their equity stake as See Remarks.
Based on SEC Form 4 filings, Leiden Dworak has been a net neutral trader of TCRX stock. They have purchased $0 and sold $0 worth of shares.
Leiden Dworak's most recent insider trade was on Jan 20, 2026, when they sold 100,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted